{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"200 days post allo"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"1 Year post allo"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Number of subjects with non-relapse mortalities post allogeneic transplant.","groups":[{"description":"See Detailed Description\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo transplantation\n\nBortezomib: Given SC\n\nCyclosporine: Given IV\n\nCyclosporine: Given PO\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given PO\n\nNonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation\n\nPeripheral Blood Stem Cell Transplantation: Undergo transplantation\n\nSyngeneic Bone Marrow Transplantation: Undergo transplantation\n\nTotal-Body Irradiation: Undergo radiotherapy","id":"OG000","title":"Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"200 and 365 days after allo","title":"Number of Patients With Non-relapse Mortality","type":"SECONDARY","unitOfMeasure":"Participants"}